Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)

Peter Goldschmidt

Chairman of the Executive Board/CEO


Since Sep. 1st, 2018, Peter Goldschmidt is CEO of STADA Arzneimittel AG. He strongly pursuits the STADA vision, to be the partner of choice in generics, specialty medicines and consumer health in Europe and selected emerging markets, while continuously outgrowing the industry in terms of growth and profit.

Peter Goldschmidt has 30 years’ experience and success in the pharmaceutical industry. He worked in OTC, Generics and the innovative Pharma Business in Asia, Europe and the US in several different leadership functions. From 2013 through 2018, Peter Goldschmidt was President of Sandoz US and Head of North America. He served on the Board of Directors as Vice Chair of Association for Accessible Medicines (AAM), the generics and biosimilar industry association in the U.S. Prior to this, he was Head of Sandoz Central and Eastern Europe and member of the Global Sandoz Executive Committee.

Over the past four years at STADA, Peter Goldschmidt has led the group on a cultural journey, implementing a growth mindset culture based around the common purpose of “Caring for People’s Health as a Trusted Partner”. By ensuring that all of STADA’s almost 13,000 employees worldwide truly live the four STADA values of Agility, Entrepreneurship, Integrity and One STADA, which has led the group in consistently delivering above-market sales and profit growth. As a top-four supplier of both consumer healthcare and generic products in Europe, STADA helps millions of people to lead healthy, dignified and fulfilled lives. In general, the company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.

A German national, he is a graduate in politics and economic geography – and hold a master’s degree in sociology – from the University of Muenster in Germany. He has completed post-graduate studies at the London Business School, UK, and at the Harvard Business School and Stanford Business School in the US.